Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals of 6 through 47 months of age on the day of informed consent.~* Individuals whose parent(s)/Legally Acceptable Representative (LAR) have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry.~* Individuals who can comply with study procedures including follow-up~* Individual is in generally good health as per the Investigator's medical judgement~Exclusion Criteria:~* Acute (severe) febrile illness~* History of any anaphylaxis, serious vaccine reactions or hypersensitivity, including allergic reactions, to any component of vaccine or medical equipment whose use is foreseen in this study~* A known history of Guillain-Barre Syndrome or other demyelinating diseases such as encephalomyelitis and transverse myelitis~* Any other clinical condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study~* Received influenza vaccination or has had documented influenza disease in the last 6 months prior to informed consent.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 47 Months
- Healthy Volunteers: t

Study Arms:
- QIVc (Type: EXPERIMENTAL): Cell-derived Quadrivalent Influenza Vaccine containing 2 influenza type A strains and 2 influenza type B strains
- Comparator QIV (Type: ACTIVE_COMPARATOR): Comparator Quadrivalent Influenza Vaccine containing 2 influenza type A strains and 2 influenza type B strains

Based on this trial design, predict the completion outcome and termination type (if applicable).